BioSpace News Archive

Drug Development

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it has obtained correspondence from the Office of Vaccines Research and Review of the U.S. Food and Drug Administration (FDA) regarding the Company’s plans to submit a Biologics License Application (BLA) to support product approval of SER-109 for recurrent C. difficile infection (CDI). After obtaining highly statistically significant topline Phase 3 ECOSP

September 11, 2020
·
8 min read
Business

Invitae Appoints Kimber Lockhart to its Board of Directors

-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur --

September 11, 2020
·
2 min read